ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Postbiotic-Inducing Ganoderma applanatum Polysaccharide Repairs the Intestinal Barrier via a Phocaeicola vulgatus - Tridecylic Acid Axis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Intestinal barrier dysfunction is a pathological hallmark of ulcerative colitis (UC), yet therapeutic strategies that precisely restore epithelial integrity remain limited. Here, we identified four distinct polysaccharide fractions from Ganoderma applanatum (GAPs) and pinpointed GAP2 as the principal bioactive component that significantly ameliorates DSS-induced colitis and intestinal barrier injury. Furthermore, experiments using germ-free mice and fecal microbiota transplantation show that the barrier-repairing efficacy of GAP2 depends on the gut microbiota and their metabolic outputs. This indicates that GAP2 acts as a microbiota-directed modulator, exerting health benefits by enriching Phocaeicola vulgatus and tridecylic acid. P. vulgatus degrades GAP2 via GH16, facilitating fatty-acid metabolism to generate tridecanoic acid (absent in the mutant), which may activate the Rho/CDC42 pathway in intestinal epithelial cells to promote tight-junction assembly, thereby restoring barrier integrity. Notably, a meta-analysis of UC patient cohorts revealed that both the abundance of P. vulgatus and its capacity for tridecylic acid biosynthesis were significantly decreased. Our findings establish GAP2 as a potent postbiotic inducer that repairs the intestinal barrier via a potential P. vulgatus-tridecylic acid-Rho/CDC42 axis. This work highlights the therapeutic potential of targeting this newly identified microbe-metabolite-signaling axis for the treatment of UC and related mucosal inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.